Bill > HR3010

This bill aims to disallow tax deductions for direct-to-consumer (DTC) advertising of prescription drugs and compounded drugs. Specifically, the bill defines direct-to-consumer advertising as any advertisement about a covered drug that is primarily targeted to the general public, including through broadcast media, direct mail, billboards, internet, social media, and digital platforms. The only exception to this definition is advertisements published in journals and periodicals. The bill applies to drug sponsors and owners of outsourcing facilities, preventing them from claiming tax deductions for such advertising expenses. The covered drugs include prescription drug products and drugs compounded in accordance with specific sections of the Federal Food, Drug, and Cosmetic Act. The amendments would take effect for amounts paid or incurred after the date of the bill's enactment, applying to taxable years ending after that date. The primary intent appears to be discouraging widespread pharmaceutical advertising to consumers by removing the financial incentive of tax deductions.

Budget and Finance

https://www.congress.gov/bill/119th-congress/house-bill/3010/all-info